05/08/2026
Science ❤️
Babies were born with no arms at all, or with hands that grew like flippers from their shoulders. Some had malformed hearts, or were deaf, or blind. Roughly half did not survive infancy. West Germany counted thousands of such children; Britain, hundreds; and more turned up in Canada, Japan, Sweden, Australia -- forty-six countries in all, upward of 10,000 children in the space of four years. The United States had seventeen. The difference was a new medical officer at the FDA named Frances Oldham Kelsey, who had been on the job barely a month when the application for thalidomide landed on her desk -- she refused to approve it.
"Most of the things they called me," Kelsey said later, "you wouldn't print." For more than a year the representatives of the drug's maker crowded into her office and rang her telephone at all hours, contacting her and her superiors some fifty times in all to complain that the newest medical officer at the FDA was a nitpicker, a bureaucrat, and in all likelihood not very bright -- a Washington Post profile would later credit her "stubbornness and skepticism" with averting a catastrophe.
The law gave her no way to say no once and be done. An application the agency failed to act on within sixty days became valid automatically, and the drug could go on sale, so that every sixty days, as the pressure mounted, Kelsey had to gather herself and reject it again.
The file had reached her in September of 1960 from the Richardson-Merrell Company of Cincinnati, which expected a formality, since thalidomide was already being sold across Europe and the Commonwealth and the firm had booked its American launch for the following spring, advertising the drug as so mild it was safe for children and for the nausea of early pregnancy. What Kelsey found in the application was not reassurance but its absence -- safety claims that struck her as more testimonial than evidence.
"Here was a drug that looked like it should be no problem," she recalled, "but at the same time there was just a feeling that there was something in the data, or the absence of data, that was a cause of concern."
That feeling hardened into alarm in December, when she read in the British Medical Journal a physician's account of patients who, after long use of thalidomide, had developed a strange numbness and tingling in their hands and feet. If the drug could work that quiet damage on the nerves of a grown adult, she wanted to know what it might do to the far more delicate business of a developing child. She asked for more, and kept asking, and the answers kept arriving from a company she believed was, in her own careful phrase, "at no time being wholly frank with me."
The instinct to distrust an easy answer was skepticism cultivated over the course of a long career. Frances Oldham was born in 1914 in Cobble Hill, British Columbia, finished high school at fifteen, and took her degree at McGill at twenty, straight into a Depression whose laboratories were not inclined to hire women -- "when a woman took a job in those days," she remembered, "she was made to feel as if she was depriving a man of the ability to support his wife and child."
A professor suggested she write to Eugene Geiling, then assembling a pharmacology department at the University of Chicago, and Geiling wrote back offering her a research post addressed to Mr. Oldham, having assumed that anyone doing such work must be a man. "My conscience tweaked me a bit," she said. "Should I write and explain that Frances with an 'e' is female and with an 'i' is male?" Her supervisor told her not to be ridiculous -- sign it, add "Miss" in brackets, and go -- and she went, becoming in time the first woman to earn a doctorate in pharmacology, though she never quite stopped wondering "whether, if my name had been Elizabeth or Mary Jane, I would have gotten that first big step up."
The training that followed was, without her knowing it, a preparation for the one file that would matter most. In Chicago she helped investigate a sulfa drug that had killed a 107 people, many of them children, because its maker had dissolved it in an industrial solvent and tested the result for taste but not for safety -- the very scandal that had brought the modern FDA into being.
She took her doctorate in 1938 and, researching antimalarial compounds, made the discovery that would matter most two decades later: that certain drugs pass straight through the placenta from a mother into the child she carries. By the time she reached Washington with a medical degree she had spent twenty years learning exactly the lesson the thalidomide file would require -- that what a drug does to a grown woman tells you dangerously little about what it does to the fetus inside her.
The proof came, when it came, from Germany. In November of 1961 the pediatrician Widukind Lenz traced the epidemic of malformed infants to thalidomide, and within weeks the German government had withdrawn it; Merrell protested that the evidence was inconclusive, held on into the spring of 1962, and at last gave up and withdrew its application.
But the drug had already crossed the border. Under the rules of the day a manufacturer could distribute an unapproved medicine to any physician willing to file it under the word "investigational," and Merrell had scattered some two and a half million tablets among more than a thousand American doctors, reaching by later estimates fifteen to twenty thousand patients, several hundred of them pregnant -- which is why, when the alarm finally sounded, FDA staff had to fan out across the country in search of the doctors and the pills, and why the American toll was seventeen rather than none.
None of it was public until the morning of July 15, 1962, when the Washington Post ran a front page story under the headline "'Heroine' of FDA Keeps Bad Drug Off Market," Kelsey's photograph above the fold. The public outrage it loosed forced Washington's hand: within months Congress passed the Kefauver-Harris Amendment, which required for the first time that a company prove a drug effective as well as safe, that patients be told when they were being given something experimental, and that the FDA be given teeth to enforce it.
Kelsey was made head of the FDA's new Investigational Drug Branch, and later led its Division of Scientific Investigations for more than two decades, writing and then enforcing the rules that govern how experimental drugs are tested on people. She had turned one careful scientist's skepticism into a system -- one that no longer depended on a single person happening to ask the right questions. The standards she built -- scientific rigor, informed consent, honest data -- are now the ordinary practice of the industrialized world.
On August 7, 1962, President Kennedy gave Kelsey the President's Award for Distinguished Federal Civilian Service, the highest honor the civil service confers and one that only a single woman had received before her. Characteristically, she deflected it, calling herself "very much a last minute addition" and accepting on behalf of the many colleagues she said had shared the work.
The historian Daniel Carpenter gave Kelsey her due: "She had a huge effect on the science that we all take for granted today." She stayed at the agency for forty-five years, retiring in 2005 at 90. Six years later, at 96, she accepted the first of a new FDA award for courage that now bears her name -- frail by then, and escorted by her two daughters.
Kelsey, who died at 101 in 2015, never once called it heroism. Asked, near the end, about the year she had spent being harangued, she gave an account with no drama in it whatsoever. "Representatives for the company thought I was crazy because it was such a popular drug in Europe, and they were losing money by my pigheadedness," she said. "I held my ground. I just wouldn't approve it." A generation of American children grew up whole because she did.
To explore her story in greater depth, "Frankie: How One Woman Prevented a Pharmaceutical Disaster" -- the first biography of Frances Kelsey -- follows the quiet, matter-of-fact scientist who faced down a pharmaceutical giant and reshaped drug safety in America and around the world at https://www.amightygirl.com/frankie
For the definitive account of her whole life and career, "Frances Oldham Kelsey, the FDA, and the Battle Against Thalidomide" traces Kelsey from her childhood on Vancouver Island through the thalidomide fight and the decades of drug-safety work that followed, at https://bookshop.org/a/8011/9780197632543 (Bookshop) and https://amzn.to/4fN8Flf (Amazon)
For more about the buried scandal behind Kelsey's stand -- the millions of unmarked thalidomide pills American companies had already slipped to thousands of unwitting patients, pregnant women among them -- we recommend "Wonder Drug: The Secret History of Thalidomide in America and Its Hidden Victims" at https://bookshop.org/a/8011/9780525512264 (Bookshop) and https://amzn.to/4pUXI5M (Amazon)
For books to show kids how science can help find a solution to problems around us, we recommend "Charlotte the Scientist Finds A Cure" for ages 4 to 8 (https://www.amightygirl.com/charlotte-the-scientist-finds-a-cure), "Ada Twist, Scientist" for ages 4 to 9 (https://www.amightygirl.com/ada-twist-scientist), and "Dragons and Marshmallows" for ages 6 to 9 (https://www.amightygirl.com/dragons-and-marshmallows)
To introduce children and teens to more inspiring female scientists, visit our blog post, "Ignite Her Curiosity: 60 Books to Inspire Science-Loving Mighty Girls," at https://www.amightygirl.com/blog?p=13914
For a documentary about one country's experience with thalidomide -- and the victims long fight for justice -- the story of Ireland's Thalidomide Scandal is told at https://www.youtube.com/watch?v=zw1xRkuPPQA
